Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients

Journal of Viral Hepatitis

Volumn 18, Issue 8, 2011, Pages 580-586

  Moucari, R ^a,b,c   Boyer, N ^a,b,c   Ripault, M P ^a,b,c   Castelnau, C ^a,b,c   Mackiewicz, V ^a   Dauvergne, A ^a   Valla, D ^a,b,c   Vidaud, M ^a   Chanoine, M H N ^a   Marcellin, P ^a,b,c  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

chronic hepatitis B; hepatitis B surface antigen; hepatitis B virus; nucleoside analogues; sustained virological response

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; VIRUS DNA;

ACCURACY; ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADENINE; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POLYETHYLENE GLYCOLS;

EID: 79960678798     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01332.x     Document Type: Article

References (30)

1. Hadziyannis SJ,. Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 130-141. (Pubitemid 43668255)
2. European association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
3. Perrillo RP,. Therapy of hepatitis B-viral suppression or eradication? Hepatology 2006; 43 (Suppl. 1): S182-S193.
4. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751. (Pubitemid 44958517)
5. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
6. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020. (Pubitemid 43357805)
7. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
8. Hadziyannis SJ, Sevastianos V, Rapti IN, Tassopoulos N,. Sustained biochemical and virologic remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. Hepatology 2006; 44 (Suppl. 1): 231A.
9. Serfaty L, Thabut D, Zoulim F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study. Hepatology 2001; 34: 573-577. (Pubitemid 32786649)
10. Sarin SK, Kumar M, Kumar R, et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005; 100: 2463-2471.
11. Sarin SK, Sood A, Kumar M, Arora A, Amrapurkar D, Sharma BC,. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102: 96-104. (Pubitemid 46072048)
12. Zoulim F, Perrillo R,. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 (Suppl. 1): S12-S19.
13. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217. (Pubitemid 39296307)
14. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
15. Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-250. (Pubitemid 40216241)
16. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129. (Pubitemid 40091801)
17. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684. (Pubitemid 44433724)
18. Piccolo P, De Melia L, Bandiera F, et al. Peginterferon alpha-2a plus adefovir dipivoxil vs. peginterferon alpha-2a monotherapy for 48 weeks in HBeAg-negative chronic hepatitis B: final results of the PEG for B randomized multicenter trial. Gastroenterology 2008; 134: A760.
19. Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13: 57-66. (Pubitemid 351541674)
20. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 137: 459-467.
21. Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136: 2169-2179.
22. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137: 2002-2009.
23. Moucari R, Martinot-Peignoux M, Mackiewicz V, et al. Influence of HBV genotypes on HBsAg kinetics in HBeAg-negative patients treated with pegylated interferon alfa-2a. Antivir Ther 2009; 14: 1183-1188.
24. Bonino F, Marcellin P, Lau GK, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg negative chronic hepatitis B. Gut 2007; 56: 699-705. (Pubitemid 46662938)
25. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157.
26. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150.
27. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ,. Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73-82. (Pubitemid 46340428)
28. Moucari R, Lada O, Marcellin P,. Chronic hepatitis B: back to the future with HBsAg. Expert Rev Anti Infect Ther 2009; 7: 633-636.
29. Perrillo RP,. Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns. Hepatology 2009; 49: 1063-1065.
30. Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50: 1084-1092.